AZDOR
TEVA PHARMACEUTICALS USA, Inc.
Application Filed: 2022-05-05
Trademark Application Details
Mark For: AZDOR™ trademark registration is intended to cover the categories of
The trademark application has been accepted by the Office (has met the minimum filing requirements) and has not yet been assigned to an examiner.
| Research |
OneLook
Acronym Finder
|
| Serial Number | 97396865 |
| Mark Literal Elements | AZDOR |
| Mark Drawing Type | 4 - STANDARD CHARACTER MARK |
| Mark Type | Trademark |
| Current Location | NEW APPLICATION PROCESSING 2022-05-09 |
| Basis | 1(b) |
| Class Status | ACTIVE |
| Primary US Classes |
|
| Primary International Class |
|
| Filed Use | No |
| Current Use | No |
| Intent To Use | Yes |
| Filed ITU | Yes |
| 44D Filed | No |
| 44E Current | No |
| 66A Current | No |
| Current Basis | No |
| No Basis | No |
| Attorney Name | Laurence Rickles |
Timeline
| 2022-05-05 | Application Filed |
| 2022-05-09 | Location: NEW APPLICATION PROCESSING |
| 2022-05-09 | Status: Live/Pending |
| 2022-05-09 | Status: New application will be assigned to an examining attorney approximately 6 months after filing date. |
| 2022-05-09 | Transaction Date |
Trademark Parties (Applicants & Owners)
| Party: |  TEVA PHARMACEUTICALS USA, Inc. |
| Address | Building A 400 Interpace Parkway Parsippany, NEW JERSEY UNITED STATES 07054 |
| Legal Entity Type | Corporation |
| Legal Entity State | DELAWARE |
Documents
 Application | 2022-05-05 | |
| Drawing | 2022-05-05 |
Attorney of Record
Good, Services, and Codes
| International Codes: | 5 |
| U.S. Codes: | 005,006,018,044,046,051,052 |
| Type Code | Type |
|---|---|
| GS0051 | Pharmaceutical preparations for the prevention and treatment of Alzheimer's disease; Pharmaceutical preparations for the prevention and treatment of depression; Pharmaceutical preparations for the prevention and treatment of psychological disorders; Pharmaceutical preparations for the prevention and treatment of diabetes and diabetic neuropathy; Pharmaceutical preparations for the prevention and treatment of cardiovascular and blood pressure disorders; Pharmaceutical preparations for the prevention and treatment of irritable bowel syndrome; Pharmaceutical preparations for the prevention and treatment of neurodegenerative diseases and disorders; Pharmaceutical preparations for the prevention and treatment of osteoporosis; Pharmaceutical preparations for the prevention and treatment of pain and neuropathic pain; Pharmaceutical preparations for the prevention and treatment of peripheral nervous system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of digestive tract, gastrointestinal and dermatological diseases and disorders; Pharmaceutical preparations for the prevention and treatment of respiratory system diseases and disorders; Pharmaceutical preparations for the prevention and treatment of sexual dysfunction; Pharmaceutical preparations for the prevention and treatment of symptoms associated with uterine fibroids; Pharmaceutical preparations for the prevention and treatment of urinary incontinence and overactive bladder; Pharmaceutical preparations for the prevention and treatment of AIDS-related disorders; Pharmaceutical preparations that support, encourage and promote bone strength; Pharmaceutical preparations that support, encourage and promote bone health; Pharmaceutical preparations used in the treatment of bone disorders and bone diseases; Pharmaceutical preparations, namely injectable contraceptives; Pharmaceutical preparations, namely, contraceptive preparations; Pharmaceutical preparations, namely fertility enhancement preparations; Pharmaceutical preparations, namely, hormone replacement therapy preparations; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical agents affecting the central nervous system; Pharmaceutical agents affecting circulatory systems; Pharmaceutical agents affecting sensory organs; Pharmaceutical agents affecting urogenital organs; Pharmaceutical agents affecting peripheral nervous system; Pharmaceutical preparations, namely, oral and injectable contraceptives, women's hormone replacement medications |
Trademark Filing History
| Description | Date | Proceeding Number |
|---|---|---|
| NEW APPLICATION ENTERED IN TRAM | 2022-05-09 |
uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.
While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.
All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.
| 